Back to Search Start Over

SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment

Authors :
Manuel Montero-Odasso
Quincy J. Almeida
Amer M. Burhan
Richard Camicioli
Julien Doyon
Sarah Fraser
Karen Li
Teresa Liu-Ambrose
Laura Middleton
Susan Muir-Hunter
William McIlroy
José A. Morais
Frederico Pieruccini-Faria
Kevin Shoemaker
Mark Speechley
Akshya Vasudev
G. Y. Zou
Nicolas Berryman
Maxime Lussier
Leanne Vanderhaeghe
Louis Bherer
Source :
BMC Geriatrics, Vol 18, Iss 1, Pp 1-15 (2018)
Publication Year :
2018
Publisher :
BMC, 2018.

Abstract

Abstract Background Physical exercise, cognitive training, and vitamin D are low cost interventions that have the potential to enhance cognitive function and mobility in older adults, especially in pre-dementia states such as Mild Cognitive Impairment (MCI). Aerobic and progressive resistance exercises have benefits to cognitive performance, though evidence is somewhat inconsistent. We postulate that combined aerobic exercise (AE) and progressive resistance training (RT) (combined exercise) will have a better effect on cognition than a balance and toning control (BAT) intervention in older adults with MCI. We also expect that adding cognitive training and vitamin D supplementation to the combined exercise, as a multimodal intervention, will have synergistic efficacy. Methods The SYNERGIC trial (SYNchronizing Exercises, Remedies in GaIt and Cognition) is a multi-site, double-blinded, five-arm, controlled trial that assesses the potential synergic effect of combined AE and RT on cognition and mobility, with and without cognitive training and vitamin D supplementation in older adults with MCI. Two-hundred participants with MCI aged 60 to 85 years old will be randomized to one of five arms, four of which include combined exercise plus combinations of dual-task cognitive training (real vs. sham) and vitamin D supplementation (3 × 10,000 IU/wk. vs. placebo) in a quasi-factorial design, and one arm which receives all control interventions. The primary outcome measure is the ADAS-Cog (13 and plus modalities) measured at baseline and at 6 months of follow-up. Secondary outcomes include neuroimaging, neuro-cognitive performance, gait and mobility performance, and serum biomarkers of inflammation (C reactive protein and interleukin 6), neuroplasticity (brain-derived neurotropic factor), endothelial markers (vascular endothelial growth factor 1), and vitamin D serum levels. Discussion The SYNERGIC Trial will establish the efficacy and feasibility of a multimodal intervention to improve cognitive performance and mobility outcomes in MCI. These interventions may contribute to new approaches to stabilize and reverse cognitive-mobility decline in older individuals with MCI. Trial Registration Identifier: NCT02808676. https://www.clinicaltrials.gov/ct2/show/NCT02808676.

Details

Language :
English
ISSN :
14712318
Volume :
18
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Geriatrics
Publication Type :
Academic Journal
Accession number :
edsdoj.beeea0f39dac4e5d9cf47ac0aeabcd14
Document Type :
article
Full Text :
https://doi.org/10.1186/s12877-018-0782-7